A5102815230- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Aging, Elder Care, and Social Issues
- Estrogen and related hormone effects
- Health, Medicine and Society
- Social Policies and Family
- Advanced Breast Cancer Therapies
- Palliative Care and End-of-Life Issues
- Lung Cancer Treatments and Mutations
- French Urban and Social Studies
- Global Health Care Issues
- Migration, Identity, and Health
- Insurance, Mortality, Demography, Risk Management
- Lung Cancer Research Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- Healthcare Decision-Making and Restraints
- Healthcare Systems and Practices
- Demographic Trends and Gender Preferences
- Island Studies and Pacific Affairs
- Lung Cancer Diagnosis and Treatment
- Migration, Aging, and Tourism Studies
- Patient-Provider Communication in Healthcare
- Bone health and treatments
Université Paris Nanterre
2024
Institut national d'études démographiques
1994-2014
Université de franche-comté
2014
L'Hôpital Nord Franche-Comté
2003-2014
Université de Rennes
2014
Centre Hospitalier Universitaire de Rennes
2014
Assistance Publique – Hôpitaux de Paris
2006-2014
Centre National de la Recherche Scientifique
2014
Chia-Yi Christian Hospital
2009
Centre Hospitalier de Rochefort
2009
PURPOSE: To compare the efficacy and tolerability of tamoxifen with that letrozole, an oral aromatase inhibitor, as first-line therapy in postmenopausal women advanced breast cancer. PATIENTS AND METHODS: Nine hundred seven patients were randomly assigned letrozole 2.5 mg once daily (453 patients) or 20 (454 patients). Patients had estrogen receptor– and/or progesterone receptor–positive tumors, both receptors unknown. Recurrence during adjuvant antiestrogen within following 12 months prior...
PURPOSE We designed a prospective randomized trial to compare vinorelbine and cisplatin (NVB-P) with vindesine (VDS-P) evaluate whether the best of these regimens affords survival benefit compared alone (NVB), an outpatient regimen, in patients non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Forty-five centers included 612 this study: 206 on NVB-P, 200 VDS-P, NVB. Vinorelbine was administered at dose 30 mg/m2 weekly, 120 days 1 29 then every 6 weeks, 3 weekly for weeks other week....
PURPOSE: Radiotherapy for head and neck cancer causes acute chronic xerostomia mucositis. Amifositine its active metabolite, WR-1065, accumulate with high concentrations in the salivary glands. This randomized trial evaluated whether amifostine could ameliorate these side effects without compromising effectiveness of radiotherapy patients. PATIENTS AND METHODS: Patients previously untreated squamous cell carcinoma were eligible. Primary end points included incidence grade ≥ 2 xerostomia, 3...
The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen three FEC followed by docetaxel (FEC-D) as adjuvant treatment for women node-positive early breast cancer.Between June 1997 March 2000, 1,999 patients operable cancer were randomly assigned to either every 21 days cycles, or docetaxel, both given days. Hormone-receptor-positive received tamoxifen 5 years after chemotherapy. primary end point was 5-year disease-free survival...
PURPOSE This study investigated the therapeutic effects of single-agent intravenous (IV) weekly Navelbine (vinorelbine or 5'-nor-anhydro-vinblastine; Pierre Fabre Médicament, Boulogne, France), a semisynthetic vinca alkaloid, in women who had received no prior chemotherapy for locally advanced metastatic breast cancer. PATIENTS AND METHODS One hundred fifty-seven patients with assessable cancer were entered onto study. They stratified into five groups according to main tumor target: lung,...
We have investigated the correlation of irreversible charge loss during first lithium intercalation into graphite electrodes with Brunauer‐Emmett‐Teller (BET) specific surface area Timrex graphites. The typically increases a higher BET but also depends strongly on type. found that not only total external ratio between prismatic and basal surfaces affects loss. latter effect occurs because particular reactions associated losses such as solvated or "self‐discharge" intercalated (reaction...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTSensitization of titanium dioxide in the visible light region using zinc porphyrinsK. Kalyanasundaram, N. Vlachopoulos, V. Krishnan, A. Monnier, and M. GraetzelCite this: J. Phys. Chem. 1987, 91, 9, 2342–2347Publication Date (Print):April 1, 1987Publication History Published online1 May 2002Published inissue 1 April 1987https://pubs.acs.org/doi/10.1021/j100293a027https://doi.org/10.1021/j100293a027research-articleACS PublicationsRequest reuse...
Abstract BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss increase fracture risk. This study evaluated an immediate or delayed strategy of protection therapy zoledronic acid. METHODS. A total 1065 patients who were receiving adjuvant letrozole randomized to immediate‐start delayed‐start acid (4 mg intravenously biannually for 5 years). The group received if lumbar...
PURPOSE The purpose of this study was to evaluate the efficacy and tolerance recombinant human interferon gamma (rIFN-gamma) as second-line treatment in patients with persistent disease at second-look laparotomy. PATIENTS AND METHODS One hundred eight residual laparotomy were treated rIFN-gamma (20 x 10(6) IU/m2) administered intraperitoneally (IP) twice a week for 3 4 months. In absence clinically assessable disease, response assessed third-look RESULTS Of 98 patients, 31 (32%) achieved...
This multicentre, randomised phase III study compared docetaxel with 5-fluorouracil+vinorelbine in patients metastatic breast cancer after failure of neo/adjuvant or one line palliative anthracycline-based chemotherapy. One hundred and seventy-six were to receive (100 mg m−2) every 3 weeks 5-fluorouracil+vinorelbine: 5-fluorouracil (750 m−2 per day continuous infusion) D1–5 plus vinorelbine (25 D1 D5 each 3-week cycle. Eighty-six received 516 cycles docetaxel; 90 476...
The "Patients' Rights and End of Life Care" Act came into force in France 2005. It allows withholding/withdrawal life-support treatment, intensified use medications that may hasten death through a double effect, as long hastening is not the purpose decision. also specifies requirements decision-making process. This study assesses situation by examining frequency end-of-life decisions patients' physicians' characteristics, describes processes. We conducted nationwide retrospective random...
To evaluate the duration and dose intensity of epirubicin-based regimens in premenopausal patients with lymph node-positive breast cancer.Between 1986 1990, 621 operable cancer were randomly assigned to receive fluorouracil (Roche SA, Basel, Switzerland) 500 mg/m2, epirubicin (Pharmacia Milan, Italy) 50 cyclophosphamide (Asta Medica AG, Frankfurt, Germany) mg/m2 every 21 days (FEC 50) for six cycles (6 FEC 50); three (3 or same regimen 75 75) 75). All arms received chest wall irradiation at...
To assess whether an epirubicin (EPI) -based chemotherapy plus hormonal regimen improves disease-free (DFS) in women older than 65 years, with node-positive, operable breast cancer (BC), relative to tamoxifen (TAM) alone.A total of 338 patients were randomly assigned after surgery receive TAM 30 mg/d for 3 years (TAM, n = 164), or EPI mg on days 1, 8, and 15 every 28 six cycles (EPI-TAM, 174). In both arms, received radiotherapy, delivered (CT) the EPI-TAM group.The 6-year DFS rates 69.3%...
PURPOSE To evaluate long-term cardiac function in patients without disease who had received six cycles of fluorouracil 500 mg/m(2), epirubicin 50 and cyclophosphamide mg/m(2) (FEC 50) or the same regimen with 100 100) as adjuvant chemotherapy for node-positive breast cancer French Adjuvant Study Group-05 trial. PATIENTS AND METHODS One hundred fifty 50, n = 65; FEC 100, 85) were gave their informed consent enrolled assessment. The assessment included events occurring after end chemotherapy,...
Abstract Background The aim of this study was to identify factors associated with satisfaction care in cancer patients undergoing ambulatory treatment. We investigated associations between patients' baseline clinical and socio-demographic characteristics, as well self-reported quality life, care. Methods Patients chemotherapy or radiotherapy 2 centres France were invited, at the beginning their treatment, complete OUT-PATSAT35, a 35 item 13 scale questionnaire evaluating perception doctors,...
In the oncology setting, there has been increasing interest in evaluating treatment outcomes terms of quality life and patient satisfaction. The aim our study was to investigate determinants satisfaction, especially relationship between satisfaction with care their changes over time, curative cancer outpatients. Patients undergoing ambulatory chemotherapy or radiotherapy two centers France were invited complete OUT-PATSAT35, at beginning treatment, end three months after treatment. This...
We report the results of Subcutaneous Administration Propeukin Program (SCAPP) II trial an outpatient treatment in renal cell carcinoma using interleukin-2 (IL-2) and interferon alfa-2a (IFN-alpha) administered subcutaneously combination with fluorouracil (5-FU). The objective this multicenter was to confirm that IL-2, IFN-alpha, 5-FU leads a response rate greater than 20%.Patients metastatic were included study. During induction phase treatment, which lasted 10 weeks, IL-2 IFN-alpha three...